1-855-378-42281-855-378-4228
One of the outpatient rehab alternatives for individuals in Leasburg struggling with opioid dependence and addiction is called opioid maintenance therapy. Licensed facilities and doctors are certified to administer specific medications to opioid dependent people, many of which are opioid-based also and are addiction. In low enough amounts however, the client doesn't feel high and also does not experience acute cravings and isn't experiencing opioid withdrawal. Methadone is the first drug tried for this reason, but there are other options to select from.
Methadone is an opioid and is meant to be taken at an outpatient medical center certified to administer the med, which is taken on a daily basis as a pill or liquid. The cost of the drug is approximately one hundred and fifty dolloars a month. Buprenorphine is also an opiate based med, and is in pill form often taken one day on, one day off. But unlike Methadone that is only be dispensed in highly structured medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is about $300.00 a month for the generic version of the drug. There is also a version of buprenorphine that contains the ingredient naloxone, which is a drug that blocks the effects of opioids. An individual consuming this formulation, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It too is taken every day, and is priced approximately $450 a month. Naltrexone is another med taken in opioid maintenance therapy, but unlike the other drugs aforementioned it's an opioid blocker and isn't an opioid. There is an option to take this drug as a monthly injection, which is called Vivitrol. As an opioid blocker, the drug prevents someone from getting high from opioids, and in turn lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 /month.
For All Drug and Alcohol Treatment Programs In Leasburg, Click Here.
